Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (361-370 of 910) with videos related to

Pageof 91
Sort By:
American Heart Journal|January 3, 2020
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialDavid A Garcia, Deborah A Fisher, Hillary Mulder, et al.
European Journal of Preventive Cardiology|November 9, 2019
Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trialErik Berglund, Lars Wallentin, Jonas Oldgren, et al.
American Heart Journal|May 3, 2005
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary interventionPaul W Armstrong, Peter X Adams, Hussein R Al-Khalidi, et al.
American Heart Journal|January 31, 2006
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarctionManesh R Patel, Trip J Meine, Lauren Lindblad, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
JACC. Cardiovascular Interventions|March 20, 2010
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionRobert C Welsh, Christopher B Granger, Cynthia M Westerhout, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
Journal of the American Heart Association|December 21, 2018
Association Between Driving Distance From Nearest Fire Station and  Survival of Out-of-Hospital Cardiac ArrestSteen M Hansen, Carolina Malta Hansen, Christopher B Fordyce, et al.
American Heart Journal|March 28, 2003
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trialSana M Al-Khatib, Amanda L Stebbins, Robert M Califf, et al.
American Heart Journal|July 2, 2005
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapyTrip J Meine, Sana M Al-Khatib, John H Alexander, et al.
Pageof 91

Showing results (361-370 of 910) with videos related to

Sort By:
Pageof 91
American Heart Journal|January 3, 2020
Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialDavid A Garcia, Deborah A Fisher, Hillary Mulder, et al.
European Journal of Preventive Cardiology|November 9, 2019
Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trialErik Berglund, Lars Wallentin, Jonas Oldgren, et al.
American Heart Journal|May 3, 2005
Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary interventionPaul W Armstrong, Peter X Adams, Hussein R Al-Khalidi, et al.
American Heart Journal|January 31, 2006
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarctionManesh R Patel, Trip J Meine, Lauren Lindblad, et al.
European Journal of Heart Failure|February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trialR A P Weir, John J V McMurray, Margareta Puu, et al.
JACC. Cardiovascular Interventions|March 20, 2010
Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionRobert C Welsh, Christopher B Granger, Cynthia M Westerhout, et al.
Circulation|December 7, 2005
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patientsScott D Solomon, Nagesh Anavekar, Hicham Skali, et al.
Journal of the American Heart Association|December 21, 2018
Association Between Driving Distance From Nearest Fire Station and  Survival of Out-of-Hospital Cardiac ArrestSteen M Hansen, Carolina Malta Hansen, Christopher B Fordyce, et al.
American Heart Journal|March 28, 2003
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trialSana M Al-Khatib, Amanda L Stebbins, Robert M Califf, et al.
American Heart Journal|July 2, 2005
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapyTrip J Meine, Sana M Al-Khatib, John H Alexander, et al.
Pageof 91